Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Trial ID or NCT#

NCT00022048

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PURPOSE: This phase I/II trial is to see if bevacizumab works in treating patients who have myelodysplastic syndrome.

Official Title

Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Peter Greenberg
Peter Greenberg
Hematologist-Oncologist
Professor of Medicine (Hematology), Emeritus

View on ClinicalTrials.gov